ALD518 Anemia Study (1.4MB PDF)
ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small-cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled study.
ALD518 Lean Body Mass Study (1.6MB PDF)
ALD518, a humanized anti-IL-6 antibody, prevents lean body mass loss and improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.
American Society for Clinical Oncology (400K PDF)
A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.
May 2009
ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small-cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled study.
ALD518 Lean Body Mass Study (1.6MB PDF)
ALD518, a humanized anti-IL-6 antibody, prevents lean body mass loss and improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.
American Society for Clinical Oncology (400K PDF)
A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.
May 2009
